The temporal profile of the anti-PF4/heparin immune response

Blood

Volumn 113, Issue 20, 2009, Pages 4970-4976

  Greinacher, Andreas ^a   Kohlmann, Thomas ^b   Strobel, Ulrike ^a   Sheppard, Jo Ann I ^c   Warkentin, Theodore E ^c  

^a UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^b UNIVERSITY OF GREIFSWALD   (Germany)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LOW MOLECULAR WEIGHT HEPARIN; THROMBOCYTE ANTIBODY; THROMBOCYTE FACTOR 4 ANTIBODY; UNCLASSIFIED DRUG; ANTIBODY; THROMBOCYTE FACTOR 4;

ADOLESCENT; ADULT; AGED; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CHILD; CONTROLLED STUDY; DRUG EFFECT; ENZYME IMMUNOASSAY; FEMALE; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; OPTICAL DENSITY; PRIORITY JOURNAL; PROPHYLAXIS; SCHOOL CHILD; SEROCONVERSION; THROMBOSIS; ANTIBODY PRODUCTION; BLOOD; CHEMICALLY INDUCED DISORDER; GENE REARRANGEMENT; IMMUNOLOGY; INNATE IMMUNITY; METABOLISM; MIDDLE AGED; PHYSIOLOGY; THROMBOCYTOPENIA; TIME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES; ANTIBODY FORMATION; CHILD; FEMALE; HEPARIN; HUMANS; IMMUNITY, INNATE; IMMUNOGLOBULIN CLASS SWITCHING; MALE; MIDDLE AGED; PLATELET FACTOR 4; THROMBOCYTOPENIA; TIME FACTORS; YOUNG ADULT;

EID: 66549089204     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-08-173062     Document Type: Article

References (42)

1. Arepally GM, Ortel TL. Heparin-induced thrombocytopenia. N Engl J Med. 2006;355:809-817.
2. Amiral J, Bridey F, Dreyfus M, et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia [letter]. Thromb Haemost. 1992;68:95-96.
3. Greinacher A, Juhl D, Strobel U, et al. Heparin-induced thrombocytopenia: a prospective study on the incidence, platelet-activating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes. J Thromb Haemost. 2007;5:1666-1673. (Pubitemid 47091409)
4. Lindhoff-Last E, Nakov R, Misselwitz F, Breddin HK, Bauersachs R. Incidence and clinical relevance of heparin-induced antibodies in patients with deep vein thrombosis treated with unfractionated or low-molecular weight heparin. Br J Haematol. 2002;118:1137-1142. (Pubitemid 35025982)
5. Kelton JG, Sheridan D, Santos A, et al. Heparin-induced thrombocytopenia: laboratory studies. Blood. 1988;72:925-930.
6. Chong BH, Fawaz I, Chesterman CN, Berndt MC. Heparin-induced thrombocytopenia: mechanism of interaction of the heparin-dependent antibody with platelets. Br J Haematol. 1989;73:235-240. (Pubitemid 19256118)
7. Warkentin TE, Greinacher A, Koster A, Lincoff AM. Treatment and prevention of heparin-induced thrombocytopenia: ACCP evidence-based clinical practice guidelines (8th edition). Chest. 2008;133(suppl 6):340S-380S. (Pubitemid 351892970)
8. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med. 2001;344:1286-1292.
9. Lubenow N, Kempf R, Eichner A, et al. Heparin-induced thrombocytopenia: temporal pattern of thrombocytopenia in relation to initial use or reexposure to heparin. Chest. 2002;122:37-42. (Pubitemid 34754140)
10. Delves PJ, Martin SJ, Burton DR, et al. The production of effectors. In: Roitt's Essential Immunology, 11th Ed. Malden, MA: Blackwell; 2006:185-210.
11. Pötzsch B, Klövekorn WP, Madlener K. Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia [letter]. N Engl J Med. 2000;343:515. (Pubitemid 30646499)
12. Aster RH, Bougie DW. Drug-induced immune thrombocytopenia. N Engl J Med. 2007;357:580-587.
13. Von Drygalski A, Curtis BR, Bougie DW, et al. Vancomycin-induced immune thrombocytopenia. N Engl J Med. 2007;356:904-910.
14. Amanna IJ, Carlson NE, Slifka MK. Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med. 2007;357:1903-1915.
15. Zwicker JI, Uhl L, Huang WY, Shaz BH, Bauer KA. Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia. J Thromb Haemost. 2004;2:2133-2137. (Pubitemid 40185772)
16. Schenk S, El-Banayosy A, Morshuis M, et al. IgG classification of anti-PF4/heparin antibodies to identify patients with heparin-induced thrombocytopenia during mechanical circulatory support. J Thromb Haemost. 2007;5:235-241. (Pubitemid 46139443)
17. Warkentin TE, Sheppard JA, Moore JC, et al. Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need? J Lab Clin Med. 2005;146:341-346.
18. Warkentin TE, Sheppard JI, Moore JC, Sigouin CS, Kelton JG. Quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays. J Thromb Haemost. 2008;6:1304-1312.
19. Juhl D, Eichler P, Lubenow N, et al. Incidence and clinical significance of anti-PF4/heparin antibodies of the IgG, IgM, and IgA class in 755 consecutive patient samples referred for diagnostic testing for heparin-induced thrombocytopenia. Eur J Haematol. 2006;76:420-426.
20. Sheridan D, Carter C, Kelton JGA. Diagnostic test for heparin-induced thrombocytopenia. Blood. 1986;67:27-30.
21. Horsewood P, Warkentin TE, Hayward CPM, Kelton JG. The epitope specificity of heparin-induced thrombocytopenia. Br J Haematol. 1996;95:161-167.
22. Greinacher A, Michels I, Kiefel V, Mueller-Eckhardt C. A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia. Thromb Haemost. 1991;66:734-736.
23. Greinacher A, Eichler P, Lietz T, Warkentin TE. Replacement of unfractionated heparin by low-molecular-weight heparin for postorthopedic surgery antithrombotic prophylaxis lowers the overall risk of symptomatic thrombosis because of a lower frequency of heparin-induced thrombocytopenia. Blood. 2005;106:2921-2922. (Pubitemid 41510775)
24. Zinkernagel RM, Hengartner H. Regulation of the immune response by antigen. Science. 2001;293:251-253.
25. Greinacher A, Gopinadhan M, Günther JU, et al. Close approximation of two platelet factor 4 tetramers by charge neutralization forms the antigens recognized by HIT antibodies. Arterioscler Thromb Vasc Biol. 2006;26:2386-2393. (Pubitemid 44465738)
26. Bachmann MF, Zinkernagel RM. The influence of virus structure on antibody responses and virus serotype formation. Immunol Today. 1996;17:553-558.
27. Warkentin TE, Sheppard JA, Sigouin CS, et al. Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. Blood. 2006;108:2937-2941.
28. Klenner AF, Fusch C, Rakow A, et al. Benefit and risk of heparin for maintaining peripheral venous catheters in neonates: a placebo-controlled trial. J Pediatr. 2003;143:741-745. (Pubitemid 37510642)
29. Mullen MP, Wessel DL, Thomas KC, et al. The incidence and implications of anti-heparin-platelet factor 4 antibody formation in a pediatric cardiac surgical population. Anesth Analg. 2008;107:371-378.
30. Greinacher A, Levy JH. HIT happens: diagnosing and evaluating the patient with heparin-induced thrombocytopenia. Anesth Analg. 2008;107:356-358.
31. Bacsi S, De Palma R, Visentin GP, Gorski J, Aster RH. Complexes of heparin and platelet factor 4 specifically stimulate T cells from patients with heparin-induced thrombocytopenia/thrombosis. Blood. 1999;94:208-215. (Pubitemid 29300151)
32. Suvarna S, Rauova L, McCracken EK, et al. PF4/heparin complexes are T cell-dependent antigens. Blood. 2005;106:929-931. (Pubitemid 41076436)
33. Hartman V, Malbrain M, Daelemans R, Meersman P, Zachée P. Pseudo-pulmonary embolism as a sign of acute heparin-induced thrombocytopenia in hemodialysis patients: safety of resuming heparin after disappearance of HIT antibodies. Nephron Clin Pract. 2006;104:c143-c148. (Pubitemid 44875770)
34. DeEurgenio DL, Ruggiero NJ, Thomson LJ, Menajovsky LB, Herman JH. Early-onset heparin-induced thrombocytopenia after a 165-day heparin-free interval: case report and review of the literature. Pharmacotherapy. 2005;25:615-619. (Pubitemid 40471502)
35. Gruel Y, Pouplard C, Nguyen P, et al. Biological and clinical features of low-molecular-weight heparin-induced thrombocytopenia. Br J Haematol. 2003;121:786-792. (Pubitemid 36718197)
36. Gruel Y, Lang M, Darnige L, et al. Fatal effect of reexposure to heparin after previous heparin-associated thrombocytopenia and thrombosis [letter]. Lancet. 2000;336:1077-1078.
37. Rota E, Bazzan M, Fantino G. Fondaparinux-related thrombocytopenia in a previous low-molecular-weight heparin (LMWH)-induced heparin-induced thrombocytopenia (HIT). Thromb Haemost. 2008;99:779-781. (Pubitemid 351694236)
38. Paparella D, Scrascia G, Galeone A, et al. Formation of anti-PF4/heparin antibodies following cardiac surgery: influence of perioperative platelet activation, the inflammatory response, and HLA status. J Thorac Cardiovasc Surg. 2008;136:1456-1463.
39. Warkentin TE, Sheppard J-AI, Sigouin CS, Kohlmann T, Eichler P, Greinacher A. Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. Blood. 2006;108:2937-2941. (Pubitemid 44776929)
40. Liu CY, Battaglia M, Lee SH, Sun QH, Aster RH, Visentin GP. Platelet factor 4 differentially modulates CD4+CD25+ (regulatory) versus CD4+CD25- (nonregulatory) T cells. J Immunol. 2005;174:2680-2686.
41. Groom JR, Fletcher CA, Walters SN, et al. BAFF and MyD88 signals promote a lupuslike disease independent of T cells. J Exp Med. 2007;204:1959-11957
42. Allman D, Pillai S. Peripheral B cell subsets. Curr Opin Immunol. 2008;20:149-157.